scholarly journals Chest X-ray survey in the follow-up of breast cancer patients

1989 ◽  
Vol 60 (1) ◽  
pp. 102-103 ◽  
Author(s):  
S Ciatto ◽  
P Pacini ◽  
C Andreoli ◽  
S Cecchini ◽  
A Iossa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
X Ray ◽  
Chest X Ray

Detection of metastases in breast cancer patients

2008 ◽  
Vol 47 (03) ◽  
pp. 97-103 ◽  
Author(s):  
S. Mahner ◽  
S. Schirrmacher ◽  
L. Jenicke ◽  
V. Müller ◽  
C. R. Habermann ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Bone Scintigraphy ◽  
Fdg Pet ◽  
Distant Metastases ◽  
Conventional Imaging ◽  
Breast Cancer Patients ◽  
Imaging Procedures ◽  
X Ray ◽  
Chest X Ray

SummaryDistant metastases at primary diagnosis are a prognostic key factor in breast cancer patients and play a central role in therapeutic decisions. To detect them, chest X-ray, abdominal ultrasound, and bone scintigraphy are performed as standard of care in Germany and many centers worldwide. Although FDG PET detects metastatic disease with high accuracy, its diagnostic value in breast cancer still needs to be defined. The aim of this study was to compare the diagnostic performance of FDG PET with conventional imaging. Patients, methods: A retrospective analysis of 119 breast cancer patients who presented for staging was performed. Whole-body FDG-PET (n=119) was compared with chest X-ray (n=106) and bone scintigraphy (n=95). Each imaging modality was independently assessed and classified for metastasis (negative, equivocal and positive. The results of abdominal ultrasound (n=100) were classified as negative and positive according to written reports. Imaging results were compared with clinical follow-up including follow-up imaging procedures and histopathology. Results: FDG-PET detected distant metastases with a sensitivity of 87.3% and a specificity of 83.3%. In contrast, the sensitivity and specificity of combined conventional imaging procedures was 43.1% and 98.5%, respectively. Regarding so-called equivocal and positive results as positive, the sensitivity and specificity of FDG-PET was 93.1% and 76.6%, respectively, compared to 61.2% and 86.6% for conventional imaging. Regarding different locations of metastases the sensitivity of FDG PET was superior in the detection of pulmonary metastases and lymph node metastases of the mediastinum in comparison to chest x-ray, whereas the sensitivity of FDG PET in the detection of bone and liver metastases was comparable with bone scintigraphy and ultrasound of the abdomen. Conclusions: FDG-PET is more sensitive than conventional imaging procedures for detection of distant breast cancer metastases and should be considered for additional staging especially in patients with high risk primary breast cancer.

Pre-Operative Chest X-Ray (CXR) In Breast Cancer Patients - Is It Necessary?

2009 ◽  
Vol 35 (11) ◽  
pp. 1220
Author(s):  
Sarit Badiani ◽  
S. Addison ◽  
R. Hobson ◽  
A. Jewkes
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
X Ray ◽  
Chest X Ray

The Role of Chest X-Ray in the Follow-Up of Primary Breast Cancer

1983 ◽  
Vol 69 (2) ◽  
pp. 151-154 ◽  
Author(s):  
Stefano Ciatto ◽  
Andrea Herd-Smith
Keyword(s):  
Breast Cancer ◽  
Randomized Study ◽  
Breast Cancer Patients ◽  
X Ray ◽  
History Of ◽  
Small Gain ◽  
Chest X Ray ◽  
Phase Out

The results of chest X-ray (CXR) survey in the follow-up of 1697 breast cancer patients are reviewed. Intrathoracic metastases (ITM) accounted for 26% of total first recurrences, but the rate dropped to 13% if isolated ITM and to 7% if asymptomatic isolated ITM were considered. Thus the role of CXR survey was limited to the detection of 39 cases of isolated ITM in the asympatomatic phase out of 7100 patients-year for a total number of 11,543 CXR examinations. Moreover, no difference in mean survival was observed if symptomatic and asymptomatic ITM were considered and survival was calculated from the time of first treatment. A small gain of 3 months, not statistically significant, of mean life from metastases diagnosis was recorded for asymptomatic cases, which is probably entirely due to the lead time effect of anticipated diagnosis. CXR survey in breast cancer follow-up may add to the knowledge of the natural history of the disease, but it appears worthless for other purposes. Thus the high costs related to CXR survey may be unacceptable, and a randomized study on the role of CXR is suggested and justified.

scholarly journals Metformin improves the outcomes in Chinese invasive breast cancer patients with type 2 diabetes mellitus

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Tianli Hui ◽  
Chao Shang ◽  
Liu Yang ◽  
Meiqi Wang ◽  
Ruoyang Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Cancer Patients ◽  
Invasive Breast Cancer ◽  
Breast Cancer Patients ◽  
Diabetes Group ◽  
Metformin Group

AbstractEarly reports indicate that metformin, a clinical drug administered to treat type 2 diabetes mellitus (T2DM), was found to be associated with a better prognosis of cancer. The objective of this study was retrospectively analyzed the effect of metformin on the outcomes of Chinese breast cancer patients with T2DM. A total of 3757 primary invasive breast cancer patients who underwent surgery from January 2010 to December 2013 were enrolled. According to the medication treatment, all the patients were divided as non-diabetes group, metformin group and insulin group. The follow-up data for disease-free survival (DFS) and overall survival (OS) were obtained from 3553 patients (median follow up of 85 months) and estimated with the Kaplan–Meier method followed by a log-rank test. Multivariate Cox proportional hazards regression model was applied. The results showed that there was a significant survival difference among non-diabetes group, metformin group and insulin group, 5-year DFS was 85.8%, 96.1%, 73.0%, and 5-year OS was 87.3%, 97.1%, 73.3% respectively (P < 0.05). Prognostic analysis showed metformin was significantly associated with better DFS and OS. Our results suggested that metformin may have a good effect on the survival of invasive breast cancer patients with T2DM.

Sign in / Sign up

Export Citation Format

Share Document